TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00379795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Description: Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year)
Study: NCT02956993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vonapanitase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02507362

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: adjusted corneal collagen cross-linking
Description: UV-A irradiation for 7 minutes

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: accelerated corneal collagen cross-linking
Description: UV-A irradiation for 10 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: riboflavin 0.1% combined with dextran 20 %
Description: after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: riboflavin 0.1% combined with dextran 20 %
Description: after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epithelial debridement
Description: corneal epithelium will be removed by a cottons swab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: epithelial debridement
Description: corneal epithelium will be removed by a cottons swab
Study: NCT02387580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OZ439 + TPGS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OZ439 + TPGS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 Prototype 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 Prototype 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 Prototype 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 Prototype 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PQP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PQP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQP
Study: NCT00791271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Starting dose of 10mg/m\^2 given daily via intravenous infusion on days 1-5 of 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alpha-2b
Description: Starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.
Study: NCT01352806

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: identification of the lumbar interspinous space using fluoroscopy versus ultrasound versuspalpation
Description: Copmarison of multiple technique for identification of the lumbar interspinous space,which is fluoroscopy,ultrasound and palpation
Study: NCT01373983

Intervention type: DRUG
Group type: OTHER
Intervention: Ziconotide
Description: 1.25 or 2.5 mcg or 3.75 mcg i.t. according to an algorithm
Study: NCT01613755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin, dipyridamole
Description: Metformin 500 mg twice daily for four days Dipyridamole 200 mg twice daily for four days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500 mg twice daily for four days
Study: NCT03965559

Intervention type: PROCEDURE
Intervention: plasmapheresis
Description: Plasmapheresis is the removal, treatment, and return or exchange of blood plasma or components thereof from and to the blood circulation. It is thus an extracorporeal therapy (a medical procedure performed outside the body).\[Wikipedia\]~DFPP is a selectively removal of the immunoglobulin fraction from the serum and, as a result, to minimize the volume of substitution fluid required. \[Tanabe K. Double-filtration plasmapheresis. Transplantation. 2007 Dec 27;84(12 Suppl):S30-2.\]

Intervention type: PROCEDURE
Intervention: plasmapheresis
Description: Plasmapheresis is the removal, treatment, and return or exchange of blood plasma or components thereof from and to the blood circulation. It is thus an extracorporeal therapy (a medical procedure performed outside the body).\[Wikipedia\]~DFPP is a selectively removal of the immunoglobulin fraction from the serum and, as a result, to minimize the volume of substitution fluid required. \[Tanabe K. Double-filtration plasmapheresis. Transplantation. 2007 Dec 27;84(12 Suppl):S30-2.\]
Study: NCT01175291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-0646
Description: ARM A will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil \[5-FU\] + Bevacizumab) + MK-0646 (Investigational).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ARM B will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil \[5-FU\] + Bevacizumab) + placebo: standard of care chemotherapy plus placebo.
Study: NCT01219231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 6 months of aerobic exercise

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: 6 months of aerobic exercise
Study: NCT03170674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21039
Description: an electronic cigarette product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21092
Description: an electronic cigarette product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21018
Description: an electronic cigarette product
Study: NCT02372487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil citrate
Description: sildenafil citrate 25 mg every 8 hours

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fluid therapy
Description: 2 liters of fluid per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fluid therapy
Description: 2 liters of fluid per day
Study: NCT02686086

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vibrating mesh nebuliser
Description: The Aerogen Solo vibrating mesh nebuliser is an approved 13 485 class II medical device (CE marked) nebuliser licenced for the delivery of physician-prescribed medications for inhalation which are approved for use with a general purpose nebuliser. It has been shown in previous laboratory and clinical studies to have superior drug delivery to standard jet nebulisers.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard hospital jet nebuliser
Description: The standard hospital jet nebuliser refers to the nebuliser in clinical use currently throughout Beaumont Hospital and used for the administration of nebulised medications

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combined salbutamol 2.5 mg and ipratropium 0.5mg nebule
Description: All patients admitted to hospital with an exacerbation of COPD are administered nebulised bronchodilators (salbutamol 2.5mg/ipratropium 0.5mg combination) as standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined salbutamol 2.5 mg and ipratropium 0.5mg nebule
Description: All patients admitted to hospital with an exacerbation of COPD are administered nebulised bronchodilators (salbutamol 2.5mg/ipratropium 0.5mg combination) as standard of care
Study: NCT01309035

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: Surgery for OA knee pains

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty
Description: Surgery for OA knee pains
Study: NCT03768947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat therapy via hot water immersion
Description: Participants will be asked to participate in a 4-week heat therapy intervention, which consists of \~12-15 visits (45 min each) of immersion in to a hot tub.
Study: NCT04576598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-management program to increase physical activity levels
Description: Information and Communication Technologies will be used to carry out various remote sessions. The sessions will address important issues to promote self-management of sedentary lifestyle by stroke survivors. Additionally, a peer support group will be created in order to improve adherence to the program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education information
Description: Education on the importance of active lifestyle habits post-stroke.
Study: NCT02447315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: oral
Study: NCT03246386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole Injection [Noxafil] 300mg
Description: Single dose by intravenous infusion 300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole Injection [Noxafil] 400mg
Description: Single dose by intravenous infusion 400mg
Study: NCT04167878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printed biodegradable cervical fusion cage
Description: ACDF with 3D printed biodegradable cervical interbody fusion cage for spinal fusion procedure at one level (C2 to T1) of the cervical spine.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEEK cage
Description: ACDF with PEEK cage for spinal fusion procedure at one level (C2 to T1) of the cervical spine.
Study: NCT03381976

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention 2X/week (G2X)
Description: Participants performed resistance training (RT) composed of eight exercises performed for one set of 10-15 repetition maximum (RM). The rest interval between exercises was 2-3 min. Participants were instructed to control the speed of movement in the ratio of 1:2 for concentric and eccentric muscle actions, respectively. The progression of training loads in each exercise occurred, when a participant completed 15 repetitions in two consecutive sessions, with increases of 2-5% in exercises for the upper limbs, and 5-10% in exercises for the lower limbs. At the end of each session, one static stretching exercise at the point of discomfort for 15 seconds was performed for all major muscle groups for a total of exercises. Participants were asked not to perform any other type of organized physical exercise during the entire study period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention 3X/week (G3X)
Description: Participants performed resistance training (RT) composed of eight exercises performed for one set of 10-15 repetition maximum (RM). The rest interval between exercises was 2-3 min. Participants were instructed to control the speed of movement in the ratio of 1:2 for concentric and eccentric muscle actions, respectively. The progression of training loads in each exercise occurred, when a participant completed 15 repetitions in two consecutive sessions, with increases of 2-5% in exercises for the upper limbs, and 5-10% in exercises for the lower limbs. At the end of each session, one static stretching exercise at the point of discomfort for 15 seconds was performed for all major muscle groups for a total of exercises. Participants were asked not to perform any other type of organized physical exercise during the entire study period.
Study: NCT02989454

Intervention type: OTHER
Intervention: Assessment of exercise capacity and cardiac energetics
Description: Cardiopulmonary exercise testing and Magnetic Resonance Spectroscopy
Study: NCT02356900

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperoxic hyperbaric interval exercise training
Description: Six 30-min high-intensity interval training sessions completed 3-times a week while at 1.4 ATA of oxygen in a hyperbaric chamber.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Normoxic, normobaric, interval exercise training
Description: Six 30-min high-intensity interval training sessions completed 3-times a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Used in Hyperoxic hyperbaric interval exercise training intervention
Study: NCT03567343

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Proprietary Spearmint Extract Blend
Description: Water extracted spearmint extract and green tea blend

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo
Study: NCT04517890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine patch
Description: 5% lidocaine patch applied at 3 hours before the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham patch
Description: Sham patch containing no study medication applied 3 hours before the procedure
Study: NCT01074385

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dignity Therapy
Description: Dignity therapy is a psychotherapeutic intervention developed to address psychosocial and existential distress among terminally ill patients. Basically, it invites patients to discuss topics that matter most or how they want to be remembered. This interview is recorded and then edited and returned to the patient to be used for further reflection or for sharing with loved ones.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dignity Therapy
Description: Dignity therapy is a psychotherapeutic intervention developed to address psychosocial and existential distress among terminally ill patients. Basically, it invites patients to discuss topics that matter most or how they want to be remembered. This interview is recorded and then edited and returned to the patient to be used for further reflection or for sharing with loved ones.
Study: NCT02753439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Geistlich Bio Oss
Description: Extraction of Impacted 3rd Molars,
Study: NCT05786742

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: grade and compare reported side effects between groups
Description: Compare experimental ultra hypo fractionation (25 Gy in 5 daily fractions administered starting mid week and ending mid following week) to our standard fractionation (either 37,5 Gy given in 15 daily fractions, or 36 Gy in 12 daily fractions).~* Toxicity analysis will be quantitatively evaluated using CTCAE (v5) at 1, 2 and 5 years post-therapy, and has needed at FU visits. Kaplan-Meier statistical analysis will be used to report toxicity evolution through time.~* median IPSS scores will be reported at 3, 6, 12 months and yearly (1, 2, 3, 4 et 5) post-therapy. IPSS median time to baseline return will be calculated.~* IPSS urinary scores, sexual function (SHIM) and GI toxicity (CTCAE-v5) and quality of life questionnaires ( EPIC-26) will be given at 3, 6 months and yearly thereafter (1, 2, 3, 4 et 5) post-treatment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: grade and compare reported side effects between groups
Description: Compare experimental ultra hypo fractionation (25 Gy in 5 daily fractions administered starting mid week and ending mid following week) to our standard fractionation (either 37,5 Gy given in 15 daily fractions, or 36 Gy in 12 daily fractions).~* Toxicity analysis will be quantitatively evaluated using CTCAE (v5) at 1, 2 and 5 years post-therapy, and has needed at FU visits. Kaplan-Meier statistical analysis will be used to report toxicity evolution through time.~* median IPSS scores will be reported at 3, 6, 12 months and yearly (1, 2, 3, 4 et 5) post-therapy. IPSS median time to baseline return will be calculated.~* IPSS urinary scores, sexual function (SHIM) and GI toxicity (CTCAE-v5) and quality of life questionnaires ( EPIC-26) will be given at 3, 6 months and yearly thereafter (1, 2, 3, 4 et 5) post-treatment.
Study: NCT02600780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Comparison of two anti-hyperuricemic molecules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Comparison of two anti-hyperuricemic molecules
Study: NCT04491071

Intervention type: DIAGNOSTIC_TEST
Intervention: Generalized Anxiety Disorder-7 (GAD 7)
Description: test that will evaluate persistent and excessive worry about a number of different things. People with Generalized Anxiety Disorder may anticipate disaster and may be overly concerned about money, health, family, work, or other issues. Individuals with Generalized Anxiety Disorder find it difficult to control their worry.

Intervention type: DIAGNOSTIC_TEST
Intervention: Background questionnaire
Description: questionnaire on the living conditions, socio-professional contexts and environmental conditions of the participants

Intervention type: DIAGNOSTIC_TEST
Intervention: Impact of COVID-19 questionnaire
Description: status of the patient with regard to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus)

Intervention type: DIAGNOSTIC_TEST
Intervention: Confinement and Communication During the COVID-19 Pandemic
Description: know the experience of containment and isolation during the pandemic

Intervention type: DIAGNOSTIC_TEST
Intervention: Mental Health questionnaire
Description: welfare effect

Intervention type: DIAGNOSTIC_TEST
Intervention: Patient Health Questionnaire (PHQ-9)
Description: assess depression during the pandemic

Intervention type: DIAGNOSTIC_TEST
Intervention: Post Traumatic Stress Disorder questionnaire (PTSD-8)
Description: Assessing the trauma of subjects during the pandemic

Intervention type: DIAGNOSTIC_TEST
Intervention: Experiences in Close Relationship Scale questionnaire (ECR-S)
Description: Measuring social ties and attachment of subjects
Study: NCT01452100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Patients enrolled into the study will be treated with prednisone, 20 mg/day (if body weight \<70 kg ; or 25mg/d if body weight \>70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: • Patients enrolled into the study will be treated with placebo, 20 mg/day (if body weight \<70 kg ; or 25mg/d if body weight \>70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
Study: NCT02914002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Description: A mobile kitchen visits the 16 selected communities every 2 weeks for a period of 1 year. A 30 minute cooking lesson is given by a trained instructor, the recipes have been designed to be quick and easy to make, use local and inexpensive ingredients, contain mostly vegetables and have a good taste. During the lesson, healthy habit and cooking tips are mentioned as well as the importance of cooking at home and having family meals . A printed version of the recipe is given to every participant. Every session participants are encouraged to prepare the recipe. At the end of the lesson all the participants get to taste the meal and express their opinion.
Study: NCT00630383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Hookworm Larvae
Description: 25 live hookworm will be applied to the arm and will infect transdermally. They will be eradicated after 48 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Histamine
Description: 0.01% histamine solution is pipetted onto a plaster dressing.
Study: NCT04516785

Intervention type: DIAGNOSTIC_TEST
Intervention: FIT and VOC
Description: Stool sample (FIT) analysed for blood in faeces and urine sample (VOC) analysed for the presence of volatile organic compounds
Study: NCT02466659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CIAO therapy Amblyz glasses
Description: 3-hour CIAO Therapy Amblyz glasses
Study: NCT04911985

Intervention type: DEVICE
Intervention: Measurement of the Cardiac Output/ Cardiac Index
Description: Semiinvasive Measurement of the Cardiac Output/ Cardiac Index with the Pulsion device
Study: NCT05427617

Intervention type: DRUG
Intervention: Control group
Description: Physician chosen treatment

Intervention type: DRUG
Intervention: Case group
Description: Druggable ctDNA alterations-guided therapy
Study: NCT01626937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation
Description: After nebulisation of bronchodilatators and administration of corticosteroid therapy, non invasive positive pressure ventilation will be started out of hospital and continuously in COPD patient with acute respiratory distress and respiratory acidosis, using a facial mask, with initial level of inspiratory pressure at 8 mmHg then according to VTe and/or respiratory rate; expiratory pressure at 4 mmHg then according to persistance of inspiratory work, level of FiO2 for an objective of SpO2 between 88 and 92%. In case of failure, NIV will be stopped and endotracheal intubation realized if indicate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional medical treatment
Description: Conventional medical treatment includes nebulization of bronchodilatators every 15-20 minutes until hospital and corticosteroid therapy. If indicate during out of hospital setting, endotracheale intubation will be realized. After admission in hospital, non invasive ventilation could be started.
Study: NCT02685982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhythmic Sensory Stimulation
Description: The stimulation consists of 30 minutes of daily stimulation with specially composed relaxing music tracks embedded with gamma frequency sounds of 30-70 Hz range.~In this study, the stimuli will be delivered with a portable sound device called Sound Oasis Vibroacoustic Therapy System (VTS-1000) unit, which is a low-voltage consumer product that has two built in mid to high frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the Rhythmic Sensory Stimulation with low-frequency sounds, the efficacy of the Sound Oasis VTS-1000 device to deliver the intervention will also be subject to observation.